Cardiff Oncology reports positive Phase 2 data for onvansertib in pancreatic and lung cancers

Cardiff Oncology, Inc.

mPDAC Phase 2: ORR 19% (1 confirmed PR, 3 pending) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo.
Biomarker trial: single-agent onvansertib reduced Ki67 by 86% and CA19-9 by 28% in refractory mPDAC.
Plans first-line mPDAC investigator-initiated trial of onvansertib + Gemzar/Abraxane at OHSU.
SCLC Phase 2: preliminary single-agent activity; safety confirmed; trial continues enrolling.
Conference call scheduled for Sept 26, 2023 at 5pm ET to discuss data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.